Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Vinblastin. Please consult your doctor.
CONSULT YOUR DOCTOR
Vinblastin is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Vinblastin is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Vinblastin may cause side effects which could affect your ability to drive.
SAFE IF PRESCRIBED
Vinblastin is safe to use in patients with kidney disease. No dose adjustment of Vinblastin is recommended.
However, talk to your doctor if you have any underlying kidney disease.
CAUTION
Vinblastin should be used with caution in patients with liver disease. Dose adjustment of Vinblastin may be needed. Please consult your doctor.
Use of Vinblastin may not be advised in patients with severe liver disease.
Medicine Overview of Vinblastin 10mg/vial Injection
Introduction
Vinblastin is an anti-cancer medication used in the treatment of breast cancer, kidney cancer, Hodgkin’s disease, and Non-Hodgkin's lymphoma. Vinblastin is given as an injection into the vein under the supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months...
... Show moreUses of Vinblastin
- Breast cancer
- Kidney cancer
- Hodgkin’s disease
- Non-Hodgkin's lymphoma
Side effects of Vinblastin
Common
- Nausea
- Vomiting
- Decreased appetite
- Decreased white blood cell count
- Diarrhea
How to use Vinblastin
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Vinblastin works
Vinblastin blocks replication of genetic material (DNA) in the cancer cells. Thus it stops the growth and multiplication of cancer cells.
Quick Tips
- In males vinblastine may cause aspermia (lack of semen causing infertility); in females vinblastine may cause amenorrhea (absence of menstruation), which may recover after some duration.
- Take precautions while taking vinblastine as it may cause inflammation of mouth and lips (stomatitis) and neurological toxicity.
- Avoid even accidental contamination of eyes with vinblastine, as it may cause severe irritation.
- Vinblastine may cause acute kidney disease (nephropathy) related to uric acid level.
- Tell your doctor if you are or planning to become pregnant or are breastfeeding.
Brief Description
Indication
Histiocytic lymphoma, Hodgkin's disease, Kaposi's sarcoma, Letterer-Siwe disease, Lymphocytic lymphoma, Mycosis fungoides, Testicular cancer
Administration
IV Preparation
IV push
1 mg/mL (dose/syringe); max syringe size for IVP is a 30 mL syringe & syringe should be <75% full
Powder: reconstitute w/ 10 mL NS or bacteriostatic NS to obtain 1 mg/mL soln
Continuous infusion: 250-1000 mL D5W or NS (dose)
Adult Dose
Intravenous
Cancers
Testicular CA, Squamous cell CA of head & neck, Hodgkin's Dz, Kaposi's sarcoma; histiocytic lymphoma, mycosis fungoides, & Letterer-Siwe disease (histiocytosis X)
General Dosing Ranges
3.7-18 mg/sq.meter/day IV q7-10d
1st dose 3.7 mg/sq.meter/day IV
Incr by 1.85 mg/sq.meter qweek until WBC equal 3000/cu.mm
NMT 18.5 mg/sq.meter
Hepatic impairment
Decrease dose by half if bilirubin >3 mg/dL [>51 umol/L]
Child Dose
Intravenous
Cancers
Testicular CA, Squamous cell carcinoma CA of head & neck, Hodgkin's Dz, Kaposi's sarcoma; histiocytic lymphoma, mycosis fungoides, & Letterer-Siwe disease (histiocytosis X)
General dosing ranges
2.5- 12.5 mg/sq meter IV q7-10d
1st dose 2.5 mg/sq.meter IV
Incr by 1.25 mg/sq.meter qWeek until WBC = 3000/cu.mm
No more than 12.5 mg/sq.meter
Contraindication
Severe bone marrow suppression; presence of bacterial infection; maglignant cell infiltration of bone marrow; Inj into extremity with poor circulation; porphyria; granulocytopenia. Elderly with cachexia or extreme skin ulcerations. Pregnancy; lactation. Intrathecal use may result in death.
Mode of Action
Vinblastine is M phase specific. It binds to microtubular proteins and arrests mitosis at the metaphase by disrupting mitotic spindle formation. It blocks glutamic acid utilization, thus inhibiting purine synthesis, the citric acid cycle, and the formation of urea. It may also interfere with nucleic acid and protein synthesis.
Precaution
Hepatic impairment; neurotoxicity; ischemic heart disease; preexisting pulmonary dysfunction; extravasation may cause tissue damage and pain. Discontinue immediately if extravasation occurs, with local Inj of hyaluronidase and local heat application to decrease discomfort and risk of cellulitis; remaining Inj to be injected into another vein. Routine prophylaxis against constipation recommended especially in high doses. Nadir in leukocyte count occur 4-10 days after vinblastine admin; recovery observed 7-14 days after treatment.
Lactation: not known if excreted in breast milk, do not nurse
Side Effect
1-10%
Anemia,Leukopenia,Myelosuppression,Alopecia
Frequency Not Defined
Peripheral neuropathy,Hypertension,Bronchospasm,Nausea,Vomiting,Anorexia,Diarrhea,Constipation,Paralytic ileus,Jaw pain,Aspermia,Amenorrhea
Interaction
Possible increase in vinblastine levels with aprepitant. Reduced vinblastine metabolism with miconazole. Variable interactions with phenytoin, monitor serum phenytoin levels. Reduced immune response with vaccines. Additive myelotoxicity with zidovudine. Concurrent admin of vinblastine with CYP3A inhibitors may cause an earlier onset and/or an increased severity of side effects.
Potentially Fatal: Increased toxicity of vinblastine with erythromycin. Increased neurotoxicity and myelotoxicity with azole antifungals e.g. itraconazole and posaconazole. Increased risk of severe neutropenia with ritonavir. Increased risk of acute pulmonary toxicity with mitomycin. Increased toxicity when ganciclovir is given with, immediately before or after vinblastine.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register